These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 24555235

  • 21. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z, Kovács N, Komoly S.
    Ideggyogy Sz; 2013 May 30; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract] [Full Text] [Related]

  • 22. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov 30; 11(135):101-6. PubMed ID: 24165688
    [Abstract] [Full Text] [Related]

  • 23. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N, Aschermann Z, Ács P, Bosnyák E, Deli G, Janszky J, Komoly S.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):245-50. PubMed ID: 25509365
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS.
    J Clin Neurosci; 2016 Mar 30; 25():41-5. PubMed ID: 26777085
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014 Mar 30; 114(11):145-51. PubMed ID: 25629138
    [Abstract] [Full Text] [Related]

  • 30. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Martí MJ.
    Parkinsonism Relat Disord; 2015 Aug 30; 21(8):871-6. PubMed ID: 26003410
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul 30; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P.
    Mov Disord; 2005 Mar 30; 20(3):306-14. PubMed ID: 15490461
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.